Pulsenmore Ltd. · TASE:PLSM
Pulsenmore — Investor Presentation (March 2026)
23 slides from Pulsenmore's investor presentation, Mar 18, 2026
Slide 1: Form 6-K Cover
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2026 001-43033 (Commission File Number) PULSENMORE LTD. (Exact name of Registrant as sp
Slide 2: Report of posted corporate presentation
On March 18, 2026, Pulsenmore Ltd. has posted to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.
Slide 3: Exhibit Index
EXHIBIT INDEX Exhibit No. Description 99.1 Corporate Presentation.
Slide 4: Signatures
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pulsenmore Ltd. Date: March 18, 2026 By: /s/ Eran Hirsh Eran Hirsh Chief Financial Officer
Slide 5: Pulsenmore: Transforming Maternal Health Through Home Ultrasound
Pulsenmore” Home Ultrasound Transforming Maternal Health Through Home Ultrasound NASDAQ and TASE: PLSM
Slide 6: Legal Disclaimer - Forward Looking Statement
Legal Disclaimer- Forward Looking Statement This presentation contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “go
Slide 7: io Cc Oo me} (s oO P=) n — LL.
io Cc Oo me} (s oO P=) n — LL.
Slide 8: Patient self-scan device
Patient self-scan device Connects with smartphone to capture and securely transmit ultrasound images from home Mobile App Delivers personalized, step-by- step scanning instructions directly to patient Clinician Dashboard Physicians prescribe and review scans remotely, provide real-time feedback and
Slide 9: Global leader in self-scan home ultrasound
NASDAQ and TASE: PLSM; Founded in 2014 ars @ Q Q (¢) Sie) AW Global Leader Regulatory Milestones 220,000+ successful First FDA De Novo clearance Nov patient scans ’25, Access to the U.S. market with Pulsenmore ES in with 3.6M annual deliveries; CE- initial 4 years mark already s * Unaudited and subj
Slide 10: Digital Health Transformation
6 Digital Health Transformation Remote monitoring adoption accelerating across healthcare Provider Shortages OB/GYN shortages driving home-care solu haps //ourworidindata.org heps //wrewgeansghts com /ndustry-analysts/tetal-monaorng-market Cost-Efficient Models Payers shifting toward decentralized c
Slide 11: Maternity Care Access
Linternity Care Access © Maternity Care Deserts (1918) © Low Access to Care (273) © Moderate Access to care (223) @ Access to Matemity Care (2427) e The Growing Gap Annual U.S. Deliveries A meaningful share of pregnancies require (Y 35% of U.S. counties are Rising healthcare costs maternity care des
Slide 12: Healthcare Challenges Today
Healthcare Challenges Today Growing Demand Limited Access Advanced maternal age and high- risk pregnancies increase prenatal care frequency. Rural and ethnic minority women face disparities in prenatal care. Capacity Strain Costly ED Utilization Clinics face space and staffing constraints, with wait
Slide 13: U.S. Business Model
U.S. Business Model Device Sales % 60% Single pregnancy use devices (~$1,000) for high-risk pregnancies (~20% of births) + expansion to broader prenatal segments. Recurring SaaS Revenue 40 Clinician dashboard subscriptions At-scale model: Device margin + high-margin SaaS/monitoring revenue Device Ma
Slide 14: Our Competitive Advantages
Our Competitive Advantages FDA-Cleared Innovation with Clear f 32) Road map Products Value for Patients, Providers and 7 One core platform, expandable to Paye rs . new modialities, including IVF (already approved in Israel) and CHF The first and only FDA-cleared h “Use : (in development). prenatal u
Slide 15: Scalable Manufacturing
Scalable Manufacturing Pulsenmore developed the first & only fully automated production lines for manufacturing ultrasound transducers Long-term competitive advantage Full manufacturing independence Flexibility to meet changing demand Reduced raw material costs Superior quality and reliability Lower
Slide 16: Clinical Studies & Real-World Evidence
Clinical Studies & Real-World Evidence 220K+ Remote Scans Performed to date globally 1,200 Hospitalization Days Saved at a single hospital using a hybrid care model with Pulsenmore (including other devices). 86.3% Of Scans suitable for clinical evaluation 9 Of Users (Callit survey) report reduction
Slide 17: Patient story and physician testimonials
At 39 weeks, Doria performed a home ultrasound scan. = After reviewing the images, Professor Hadar advised her to come to the hospital immediately. Within 30 minutes of arrival, she gave birth - there wasn’t even time for an epidural. Doria Marley wa Chairman, OBGYN Department, Eastern Virginia Medi
Slide 18: Strategic Partnerships & Investments
Strategic Partnerships & Investments FUJiFILM gf TELA STOCK EXCHANGE =~ CLALIT 2016 Fujifilm Investment Strategic partnership established 2020 Initial Clalit Agreement Multi-million-dollar contract with Israel's largest HMO 2021 TASE IPO Strategic partnership established 2022 GE HealthCare Major $21
Slide 19: Go-to-Market Strategy
Go-to-Market Strategy U.S. Commercial Launch '26 OB networks and hospitals Telehealth provider partnerships Employer partnerships cost savings for patients CPT 76815 available at launch Europe & APAC * Expansion via leading institutions (UK, France, Australia) Large OB clinic partnerships Reimbursem
Slide 20: Board of Directors
Board of Directors Founde Mr. Jo nh rman of the board Led several medical device and technology companies (NASDAQ: Veteran executive (NYSE: ELT, NASDAQ: MZOR), with 27 years at MDGS). PhD in Electronics & Computer Engineering, Ben-Gurion Elscint as President and CEO (1994-1998). Brings deep expertis
Slide 21: New Product in the pipeline - Follicles monitoring
New Product in the pipeline-Follicles monitoring JV IVF and fertility preservation require 4—7 ultrasound scans per cycle, creating significant clinic load and patient burden. JV Home-based follicular monitoring unlocks scalable capacity and improves patient experience. AMAR authorization in Israel
Slide 22: Growth & Strategy Outlook
Growth & Strategy Outlook 0 U.S. 6) International Commercialization '26 Expansion Launch EU and global market penetration Long-term vision (6) R&D Pipeline Expanded indications to new modalities , Al diagnostics, enhanced visualization 0 Manufacturing Automation Industry-leading cost basis and indep
Slide 23: Thank you
ill Pulsenmore” f <a ~ Thank you.